FY2017 EPS Estimates for Teladoc Inc (TDOC) Decreased by Analyst
Teladoc Inc (NYSE:TDOC) – Stock analysts at SunTrust Banks reduced their FY2017 earnings per share (EPS) estimates for shares of Teladoc in a research report issued on Monday. SunTrust Banks analyst S. Draper now expects that the health services provider will earn ($1.83) per share for the year, down from their prior forecast of ($1.65). SunTrust Banks currently has a “Buy” rating and a $40.00 target price on the stock. SunTrust Banks also issued estimates for Teladoc’s Q4 2017 earnings at ($0.67) EPS, FY2018 earnings at ($1.47) EPS and FY2019 earnings at ($0.81) EPS.
TDOC has been the subject of several other research reports. Oppenheimer increased their price target on Teladoc from $40.00 to $45.00 and gave the company an “outperform” rating in a report on Tuesday, November 21st. Zacks Investment Research cut Teladoc from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. BidaskClub cut Teladoc from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Deutsche Bank started coverage on Teladoc in a report on Friday, December 8th. They issued a “buy” rating and a $39.00 price target for the company. Finally, Citigroup started coverage on Teladoc in a report on Thursday, January 4th. They issued a “buy” rating for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Teladoc presently has a consensus rating of “Buy” and an average price target of $39.31.
Teladoc (NYSE:TDOC) opened at $33.10 on Thursday. Teladoc has a fifty-two week low of $15.65 and a fifty-two week high of $38.40. The company has a current ratio of 5.08, a quick ratio of 5.08 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $2,000.00 and a P/E ratio of -22.83.
Teladoc (NYSE:TDOC) last announced its earnings results on Wednesday, November 1st. The health services provider reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). Teladoc had a negative net margin of 45.64% and a negative return on equity of 29.70%. The firm had revenue of $68.70 million for the quarter, compared to analyst estimates of $67.53 million. During the same period in the previous year, the company earned ($0.33) EPS. Teladoc’s revenue was up 112.0% compared to the same quarter last year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. ETF Managers Group LLC purchased a new position in shares of Teladoc during the second quarter worth $104,000. Pacad Investment Ltd. purchased a new position in Teladoc in the second quarter valued at $135,000. Fred Alger Management Inc. purchased a new position in Teladoc in the second quarter valued at $139,000. Ameritas Investment Partners Inc. boosted its holdings in Teladoc by 134.2% in the second quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after purchasing an additional 2,707 shares during the period. Finally, Oppenheimer Asset Management Inc. purchased a new position in Teladoc in the second quarter valued at $166,000.
In other news, CEO Jason N. Gorevic sold 100,000 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the completion of the transaction, the chief executive officer now directly owns 718,261 shares in the company, valued at $23,695,430.39. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Mark Hirschhorn sold 35,000 shares of the firm’s stock in a transaction on Tuesday, October 17th. The stock was sold at an average price of $32.84, for a total value of $1,149,400.00. Following the transaction, the vice president now owns 20,887 shares of the company’s stock, valued at $685,929.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 210,000 shares of company stock valued at $6,889,350. Company insiders own 4.47% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/fy2017-eps-estimates-for-teladoc-inc-tdoc-decreased-by-analyst/1802640.html.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with Analyst Ratings Network's FREE daily email newsletter.